Based on the available biological knowledge, we focussed on the most prominent onco-markers of the G-CIMP-high subtype: mutation status of the alpha thalassemia/mental retardation syndrome X-linked (ATRX), isocitrate dehydrogenase (IDH) and TP53 genes. This evidence concerns the gene IDH1 and alpha thalassemia spectrum.